Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
COMPASS Pathways (CMPS)
NASDAQ:CMPS
COMPASS Pathways (CMPS) Stock Price & Analysis
1,078 Followers
CMPS Stock Chart & Stats
Day’s Range$8.31 - $8.69
52-Week Range― - ―
Previous Close$8.53
Volume244.81K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 09, 2024EPS Estimate
-$0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$49.00Price Target Upside482.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
COMPASS Pathways News
PremiumCompany Announcements
COMPASS Pathways Leadership Restructure and Board Reshuffle
Bulls Say, Bears Say
Bulls Say
Financial StabilitySufficient funding into late 2025 is projected for Compass, ensuring financial stability through pivotal Phase 3 studies and boosting investor confidence in the company's long-term prospects.
Product PotentialCompass's lead drug COMP360 shows rapid, dose-dependent benefits with good safety in treatment-resistant depression, indicating a strong potential for positive impact in the mental health market.
Regulatory MilestoneFDA's publication of guidance for psychedelic drug development and alignment with COMP360's development plan is encouraging for its path to market, signaling a clearer regulatory pathway for investors.
Bears Say
Clinical Trial DelaysCOMP-005 study has been delayed due to record-keeping procedures in the US increasing the difficulty of confirming a TRD diagnosis.
Financial PerformanceOperating expenses of $38.4mn came in higher than the expected $17.3mn mainly due to unpredictable timing on an R&D credit.
Management ChangesGeorge Goldsmith and Dr. Katya Malievskaya resigned from their board seats.
---
Ownership Overview
36.52% Insiders
0.26% Mutual Funds
7.16% Other Institutional Investors
56.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CMPS FAQ
What was COMPASS Pathways’s price range in the past 12 months?
Currently, no data Available
What is COMPASS Pathways’s market cap?
Currently, no data Available
When is COMPASS Pathways’s upcoming earnings report date?
COMPASS Pathways’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were COMPASS Pathways’s earnings last quarter?
COMPASS Pathways released its earnings results on Feb 29, 2024. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.361 by -$0.169.
Is COMPASS Pathways overvalued?
According to Wall Street analysts COMPASS Pathways’s price is currently Undervalued.
Does COMPASS Pathways pay dividends?
COMPASS Pathways does not currently pay dividends.
What is COMPASS Pathways’s EPS estimate?
COMPASS Pathways’s EPS estimate is -$0.48.
How many shares outstanding does COMPASS Pathways have?
Currently, no data Available
What happened to COMPASS Pathways’s price movement after its last earnings report?
COMPASS Pathways reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.361. Following the earnings report the stock price went down -16.977%.
Which hedge fund is a major shareholder of COMPASS Pathways?
Among the largest hedge funds holding COMPASS Pathways’s share is ARK Investment Management LLC. It holds COMPASS Pathways’s shares valued at 23M.
---
COMPASS Pathways Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (482.99% Upside)
$49.00 (482.99% Upside)
Blogger Sentiment
Bullish
CMPS Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 266.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.71%
12-Months-Change
Fundamentals
Return on Equity
-58.41%
Trailing 12-Months
Asset Growth
39.89%
Trailing 12-Months
Company Description
COMPASS Pathways
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
---
CMPS Earnings Call
Q4 2024
0:00 / 0:00
---
CMPS Stock 12 Months Forecast
Average Price Target
$49.00
▲(482.99% Upside)
Technical Analysis
Reviva Pharmaceuticals Holdings
―
Alkermes
―
ACADIA Pharmaceuticals
―
Axsome Therapeutics
―
Best Analysts Covering CMPS
1 Year
1 Year Success Rate
3/8 ratings generated profit
1 Year Average Return
-8.82%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of -8.82% per trade.
---